DOCSLIB.ORG

Quality of Tuberculosis Care Click

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quality of Tuberculosis Care Click This eBook is dedicated to the millions of people who battle TB every year We hope they get the high-quality care they need and deserve To view individual articles in the series on Quality of Tuberculosis Care, visit the Journal website: https://www.sciencedirect.com/journal/journal-of-clinical-tuberculosis-and-other- mycobacterial-diseases/special-issue/10JL8LN0VVT Articles in this series are published under CC BY-NC-ND license, and be shared/copied, with credit, for non-commercial purposes only Contents lists available at ScienceDirect J Clin Tuberc Other Mycobact Dis journal homepage: www.elsevier.com/locate/jctube Quality of Tuberculosis Care Table of Contents T 1. Quality: The missing ingredient in TB care and control Madhukar Pai, Zelalem Temesgen 2. Lessons on the quality of tuberculosis diagnosis from standardized patients in China, India, Kenya, and South Africa Benjamin Daniels, Ada Kwan, Madhukar Pai, Jishnu Das 3. Quality of drug-resistant tuberculosis care: Gaps and solutions Zarir Udwadia, Jennifer Furin 4. In the eye of the multiple beholders: Qualitative research perspectives on studying and encouraging quality of TB care in India Andrew McDowell, Nora Engel, Amrita Daftary 5. Measuring and improving the quality of tuberculosis care: A framework and implications from the Lancet Global Health Commission Catherine Arsenault, Sanam Roder-DeWan, Margaret E. Kruk 6. Implementing quality improvement in tuberculosis programming: Lessons learned from the global HIV response Daniel J. Ikeda, Apollo Basenero, Joseph Murungu, Margareth Jasmin, Maureen Inimah, Bruce D. Agins 7. Quality of TB services assessment: The unique contribution of patient and provider perspectives in identifying and addressing gaps in the quality of TB services Charlotte Colvin, Gretchen De Silva, Celine Garfin, Soumya Alva, Suzanne Cloutier, Donna Gaviola, Kola Oyediran, Tito Rodrigo, Jeanne Chauffour 8. The high-quality health system ‘revolution’: Re-imagining tuberculosis infection prevention and control Helene-Mari van der Westhuizen, Ruvandhi R. Nathavitharana, Clio Pillay, Ingrid Schoeman, Rodney Ehrlich 9. Quality of life with tuberculosis Ashutosh N. Aggarwal 10. Quality of TB care among people living with HIV: Gaps and solutions Kogieleum Naidoo, Santhanalakshmi Gengiah, Satvinder Singh, Jonathan Stillo, Nesri Padayatchi 11. Closing gaps in the tuberculosis care cascade: an action-oriented research agenda Ramnath Subbaraman, Tulip Jhaveri, Ruvandhi R. Nathavitharana 12. Quality matters: Redefining child TB care with an emphasis on quality Farhana Amanullah, Jason Michael Bacha, Lucia Gonzalez Fernandez, Anna Maria Mandalakas 20. Quality of tuberculosis care in the private health sector 21. Improving the quality of tuberculosis care in the post-pandemic world Contents lists available at ScienceDirect J Clin Tuberc Other Mycobact Dis journal homepage: www.elsevier.com/locate/jctube Quality of Tuberculosis Care Table of Contents T 13. Quality of tuberculosis care by pharmacies in low- and middle-income countries: Gaps and opportunities Rosalind Miller, Catherine Goodman 14. Implementation science to improve the quality of tuberculosis diagnostic services in Uganda Adithya Cattamanchi, Christopher A. Berger, Priya B. Shete, Stavia Turyahabwe, Moses Joloba, David AJ Moore, Lucian J. Davis, Achilles Katamba 15. Identifying gaps in the quality of latent tuberculosis infection care Hannah Alsdurf, Dick Menzies 16. User experience and patient satisfaction with tuberculosis care in low- and middle-income countries: A systematic review Danielle Cazabon, Tripti Pande, Paulami Sen, Amrita Daftary, Catherine Arsenault, Himani Bhatnagar, Kate O'Brien, Madhukar Pai 17. Tuberculosis deaths are predictable and preventable: Comprehensive assessment and clinical care is the key Anurag Bhargava, Madhavi Bhargava 18. Improving quality is necessary to building a TB-free world: Lancet Commission on Tuberculosis Michael J.A. Reid, Eric Goosby 19. What quality of care means to tuberculosis survivors Chapal Mehra, Debshree Lokhande, Deepti Chavan, Saurabh Rane 20. Quality of tuberculosis care in the private health sector Guy Stallworthy, Hannah Monica Dias, Madhukar Pai 21. Improving the quality of tuberculosis care in the post-pandemic world Jacob Bigio, Angelina Sassi, Zelalem Temesgen, Madhukar Pai 20. Quality of tuberculosis care in the private health sector 21. Improving the quality of tuberculosis care in the post-pandemic world J Clin Tuberc Other Mycobact Dis 14 (2019) 12–13 Contents lists available at ScienceDirect J Clin Tuberc Other Mycobact Dis journal homepage: www.elsevier.com/locate/jctube Editorial Quality: The missing ingredient in TB care and control T Good health is a function of the utilization of healthcare services TB field urgently needs to adopt and implement the science of quality and the quality of healthcare. In the field of global health, there is improvement (QI). But QI alone is not sufficient, since even the foun- growing awareness of the need to go beyond coverage of services and dations of TB care are weak. Countries need to invest adequate funds to improve the quality of care [1,2]. control TB, and make sure TB services are of high quality and patient- Recently, The Lancet Global Health published a landmark report centric. entitled High-quality health systems (HQSS) in the Sustainable In September 2018, the United Nations General Assembly hosted the Development Goals era: Time for a revolution [3]. In this HQSS Com- first ever High-level Meeting (UNHLM) on TB, and adopted a political mission report, the authors asserted that providing health services (i.e. declaration, which recognized that “tuberculosis is both preventable coverage) without guaranteeing a minimum level of quality is in- and curable, yet 40 per cent of people newly a ffected by tuberculosis effective, wasteful, and unethical. What is needed, the Commission are missed by public health reporting systems, and millions do not re- argued, are high-quality health systems that optimize health care in ceive quality care each year, and that tuberculosis can only be elimi- each given context by consistently delivering care that improves or nated through prevention efforts and access to quality diagnosis, maintains health, by being valued and trusted by all people, and by treatment and care, including access to affordable diagnostic tools and responding to changing population needs [3]. drug treatment, effective people-centered and community-based Throughout the report, tuberculosis (TB) is used as a key example to models of care supported by integrated care services, as well as finan- illustrate the need to go beyond coverage and focus on the quality of cing innovations” [14]. care. According to the HQSS report, more than 8 million people per The TB field must build on this emphasis on quality in the UNHLM year in low- and middle-income countries die from conditions that declaration and push all stakeholders to think beyond coverage and should be treatable by the health system. Sixty-percent of deaths from demand high quality care for all TB patients in all countries. If we are conditions amenable to health care are due to poor-quality care, serious about ending TB, we must put quality on the agenda, in addition whereas the remaining deaths result from non-utilization of the health to expanding coverage of critical interventions. system [3]. Given the importance of quality in TB care, Journal of Clinical The HQSS report provides a detailed analysis on TB deaths. Of the Tuberculosis and Other Mycobacterial Diseases, has launched a series on 946,003 TB deaths amenable to healthcare, the authors estimate that this topic. The series will cover papers on quality of TB care, approaches 469,956 (50%) are due to poor quality TB care. The remaining 476,047 to measuring quality, and quality improvement interventions. It is our deaths are due to non-utilization of healthcare services [3]. wish and hope that this series will result in a robust and sustained The report suggests that high-quality health systems could prevent conversation about quality TB care, a topic that has heretofore been 900,000 TB deaths each year [3]. In other words, by using already woefully neglected. existing tools and improving the quality of care, we can avert 50% of all TB deaths. Conflicts of interest The fact that 50% of deaths in association with TB occur despite the patient seeking medical care is a sad reflection on the current state of None. affairs. How is it acceptable that we cannot save patients with a curable, bacterial infection for which we have policies, tools and technologies? Ethical statement Why is the quality of TB care suboptimal? Patient-pathways ana- lyses from 13 countries show long, complex pathways to health care, None. private or informal sectors being the preferred first point of contact, and lack of adequate TB services at the primary care level. [4] Several Supplementary material studies show large gaps in the cascades of care, across types of TB and countries [5–7]. Supplementary material associated with this article can be found, in Simulated (standardized) patient studies in 4 countries (India, the online version, at doi:10.1016/j.jctube.2018.12.001. Kenya, China and South Africa) confirm gaps in cascades of care, and show poor quality of care in both public and private sectors, with pri- References vate sector faring worse [8–12]. Across these studies, only about a third of simulated patients with presumed TB were managed correctly at the [1] Kruk ME, Larson E, Twum-Danso NA. Time for a quality revolution in global health. primary care level. Lancet Glob Health 2016;4(9):e594–6. [2] Das J, Woskie L, Rajbhandari R, Abbasi K, Jha A. Rethinking assumptions about To end TB, we need nothing short of a quality revolution [13]. The https://doi.org/10.1016/j.jctube.2018.12.001 Received 29 November 2018; Accepted 23 December 2018 2405-5794/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). Editorial J Clin Tuberc Other Mycobact Dis 14 (2019) 12–13 delivery of healthcare: implications for universal health coverage.
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Bacille Calmette–Guérin Vaccination: the Current Situation in Europe
    EDITORIAL BCG VACCINATION POLICY IN EUROPE | Bacille Calmette–Gue´rin vaccination: the current situation in Europe Masoud Dara1,5, Colleen D. Acosta1,5, Valiantsin Rusovich2, Jean Pierre Zellweger3, Rosella Centis4 and Giovanni Battista Migliori4 on behalf of the WHO EURO Childhood Task Force members6 Affiliations: 1World Health Organization Regional Office for Europe, Copenhagen, Denmark. 2World Health Organization Country Office, Minsk, Belarus. 3Swiss Lung Association, Vaud section (LPVD), Lausanne, Switzerland. 4World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy. 5These authors contributed equally. 6For a list of the WHO EURO Childhood Task Force members and their affiliations, please see the acknowledgements section. Correspondence: G.B. Migliori, World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Via Roncaccio 16, 21049, Tradate, Italy. E-mail: [email protected] @ERSpublications A WHO EURO Task Force provides the latest evidence and a coherent policy to use BCG vaccination in Europe http://ow.ly/pusIU Tuberculosis is a major public health priority. This is not only because of its daunting morbidity and mortality rates, both globally and in Europe (summarised in figs 1 and 2)[1, 3–5], but also because of the natural history of the disease. Active (contagious) tuberculosis disease occurs after a period of latency (or subclinical infection), and different risk factors [6–13], in combination with latent infection, introduce challenges to prevention, diagnosis and treatment of the disease. Vaccination against tuberculosis, if effective, would be therefore critical to control and elimination strategies [14–16].
    [Show full text]
  • MAPPING DIGITAL MEDIA: PAKISTAN Mapping Digital Media: Pakistan
    COUNTRY REPORT MAPPING DIGITAL MEDIA: PAKISTAN Mapping Digital Media: Pakistan A REPORT BY THE OPEN SOCIETY FOUNDATIONS WRITTEN BY Huma Yusuf 1 EDITED BY Marius Dragomir and Mark Thompson (Open Society Media Program editors) Graham Watts (regional editor) EDITORIAL COMMISSION Yuen-Ying Chan, Christian S. Nissen, Dusˇan Reljic´, Russell Southwood, Michael Starks, Damian Tambini The Editorial Commission is an advisory body. Its members are not responsible for the information or assessments contained in the Mapping Digital Media texts OPEN SOCIETY MEDIA PROGRAM TEAM Meijinder Kaur, program assistant; Morris Lipson, senior legal advisor; and Gordana Jankovic, director OPEN SOCIETY INFORMATION PROGRAM TEAM Vera Franz, senior program manager; Darius Cuplinskas, director 21 June 2013 1. Th e author thanks Jahanzaib Haque and Individualland Pakistan for their help with researching this report. Contents Mapping Digital Media ..................................................................................................................... 4 Executive Summary ........................................................................................................................... 6 Context ............................................................................................................................................. 10 Social Indicators ................................................................................................................................ 12 Economic Indicators ........................................................................................................................
    [Show full text]
  • Ofcom, PEMRA and Mighty Media Conglomerates
    Ofcom, PEMRA and Mighty Media Conglomerates Syeda Amna Sohail Ofcom, PEMRA and Mighty Media Conglomerates THESIS To obtain the degree of Master of European Studies track Policy and Governance from the University of Twente, the Netherlands by Syeda Amna Sohail s1018566 Supervisor: Prof. Dr. Robert Hoppe Referent: Irna van der Molen Contents 1 Introduction 4 1.1 Motivation to do the research . 5 1.2 Political and social relevance of the topic . 7 1.3 Scientific and theoretical relevance of the topic . 9 1.4 Research question . 10 1.5 Hypothesis . 11 1.6 Plan of action . 11 1.7 Research design and methodology . 11 1.8 Thesis outline . 12 2 Theoretical Framework 13 2.1 Introduction . 13 2.2 Jakubowicz, 1998 [51] . 14 2.2.1 Communication values and corresponding media system (minutely al- tered Denis McQuail model [60]) . 14 2.2.2 Different theories of civil society and media transformation projects in Central and Eastern European countries (adapted by Sparks [77]) . 16 2.2.3 Level of autonomy depends upon the combination, the selection proce- dure and the powers of media regulatory authorities (Jakubowicz [51]) . 20 2.3 Cuilenburg and McQuail, 2003 . 21 2.4 Historical description . 23 2.4.1 Phase I: Emerging communication policy (till Second World War for modern western European countries) . 23 2.4.2 Phase II: Public service media policy . 24 2.4.3 Phase III: New communication policy paradigm (1980s/90s - till 2003) 25 2.4.4 PK Communication policy . 27 3 Operationalization (OFCOM: Office of Communication, UK) 30 3.1 Introduction .
    [Show full text]
  • Repaving the Ancient Silk Routes
    PwC Growth Markets Centre – Realising opportunities along the Belt and Road June 2017 Repaving the ancient Silk Routes In this report 1 Foreword 2 Chapter 1: Belt and Road – A global game changer 8 Chapter 2: China’s goals for the Belt and Road 14 Chapter 3: Key sectors and economic corridors 28 Chapter 4: Opportunities for foreign companies 34 Chapter 5: Unique Belt and Road considerations 44 Chapter 6: Strategies to evaluate and select projects 56 Chapter 7: Positioning for success 66 Chapter 8: Leveraging international platforms 72 Conclusion Foreword Belt and Road – a unique trans-national opportunity Not your typical infrastructure projects Few people could have envisaged what the Belt and Road However, despite the vast range and number of B&R (B&R) entailed when President Xi of China first announced opportunities, many of these are developed in complex the concept back in 2013. However, four years later, the B&R conditions, not least because they are located in growth initiative has amassed a huge amount of economic markets where institutional voids can prove to be hard to momentum.The B&R initiative refers to the Silk Road navigate. Inconsistencies in regulatory regimes and Economic Belt and the 21st Century Maritime Silk Road underdeveloped credit markets, together with weak existing initiatives. The network connects Asia, Europe and Africa, infrastructure and a maturing talent market all combine to and passes through more than 65 countries and regions with add further complexity for companies trying to deliver and a population of about 4.4 billion and a third of the global manage these projects.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis ISBN 978 92 4 154880 9
    Companion handbookCompanion tofor the the WHO programmatic guidelines management of drug-resistant tuberculosis Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis ISBN 978 92 4 154880 9 Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis This book is a companion handbook to existing WHO policy guidance on the management of multidrug-resistant tuberculosis, including the WHO guidelines for the programmatic management of drug-resistant tuberculosis, WHO interim policy guidance on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis, and the WHO interim policy guidance on the use of delamanid in the treatment of multidrug-resistant tuberculosis which were developed in compliance with the process for evidence gathering, assessment and formulation of recommendations, as outlined in the WHO Handbook for Guideline Development (version March 2010; available at http://apps.who.int/iris/ bitstream/10665/75146/1/9789241548441_eng.pdf ). WHO Library Cataloguing-in-Publication Data Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 1.Antitubercular agents – administration and dosage. 2.Tuberculosis, Multidrug-Resistant – drug therapy. 3.Treatment outcome. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154880 9 (NLM classification: WF 360) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Management of Patients with Multidrug-Resistant Tuberculosis
    INT J TUBERC LUNG DIS 23(6):645–662 STATE OF THE ART Q 2019 The Union http://dx.doi.org/10.5588/ijtld.18.0622 STATE OF THE ART SERIES MDR-TB Series editors: C Horsburgh, Christoph Lange and Carole Mitnick NUMBER 4 IN THE SERIES Management of patients with multidrug-resistant tuberculosis C. Lange, R. E. Aarnoutse, J. W. C. Alffenaar, G. Bothamley, F. Brinkmann, J. Costa, D. Chesov, R. van Crevel, M. Dedicoat, J. Dominguez, R. Duarte, H. P. Grobbel, G. Gunther,¨ L. Guglielmetti, J. Heyckendorf, A. W. Kay, O. Kirakosyan, O. Kirk, R. A. Koczulla, G. G. Kudriashov, L. Kuksa, F. van Leth, C. Magis-Escurra, A. M. Mandalakas, B. Molina-Moya, C. A. Peloquin, M. Reimann, R. Rumetshofer, H. S. Schaaf, T. Schon, ¨ S. Tiberi, J. Valda, P. K. Yablonskii, K. Dheda Please see Supplementary Data for details of all author affiliations. SUMMARY The emergence of multidrug-resistant tuberculosis availability of novel drugs such as bedaquiline allow us to (MDR-TB; defined as resistance to at least rifampicin design potent and well-tolerated personalised MDR-TB and isoniazid) represents a growing threat to public treatment regimens based solely on oral drugs. In this health and economic growth. Never before in the history article, we present management guidance to optimise the of mankind have more patients been affected by MDR- diagnosis, algorithm-based treatment, drug dosing and TB than is the case today. The World Health Organiza- therapeutic drug monitoring, and the management of tion reports that MDR-TB outcomes are poor despite adverse events and comorbidities, associated with MDR- staggeringly high management costs.
    [Show full text]
  • Evans Sagwa Aukje K
    Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Evans L. Sagwa Sagwa, EL Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Thesis Utrecht University -with ref.- with summary in Dutch Copyright © 2017 EL Sagwa. All rights reserved. The research presented in this PhD thesis was conducted under the umbrella of the Utrecht World Health Organization (WHO) Collaborating Centre for Pharmaceutical Policy and Regulation, which is based at the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht Uni- versity, The Netherlands. The Collaborating Centre aims to develop new methods for independent pharmaceutical policy research, evidence-based policy analysis and conceptual innovation in the area of policy making and evaluation in general. ISBN: 978-94-92683-40-3 Layout and printed by: Optima Grafische Communicatie, Rotterdam, the Netherlands Optimizing the Safety of Multidrug-resistant Tuberculosis Therapy in Namibia Verbeteren van de veiligheid van de behandeling van multiresistente tuberculose in Namibië (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 24 augustus 2017 des middags te 12.45 uur door Evans Luvaha Sagwa geboren op 17 november 1972 te Kakamega, Kenia Promotor: Prof.dr. H.G.M. Leufkens Copromotor: Dr. A.K. Mantel-Teeuwisse A Quote by Donna Flagg: When the Cure Is Worse Than the Disease “Not only are the folks popping these pills not happy, but they now suffer from new problems that are caused by the drugs themselves”.
    [Show full text]
  • Taliban Stormed Parliament; Bid to Confirm Defense Minister Disrupted
    Eye on the News [email protected] Truthful, Factual and Unbiased Vol:IX Issue No:317 Price: Afs.15 TUESDAY . JUNE 23 . 2015 -Saratan 02, 1394 HS www.afghanistantimes.af www.facebook.com/ afghanistantimeswww.twitter.com/ afghanistantimes UN urges Ghani to specify date Taliban stormed parliament; bid to of parliamentary elections confirm defense minister disrupted Abdul Zuhoor Qayomi AT Monitoring Desk safety whereas some of them have received minor injuries. Shekiba KABUL: The Taliban assaulted Hashemi, a MP from Kandahar KABUL: The United Nations the Parliament on Monday just province told Afghanistan Times (UN) urged President Ashraf as parliamentarians were conven- that she along with her colleagues Ghani to specify the exact date of ing for their third attempt to cast was shifted to a safer place and upcoming parliamentary elec- their vote of confidence for a de- no one was hurt. Kabul Police tions. The UN leadership in Af- fense minister. A suicide bomber spokesman Ebadullah Karemi told ghanistan hold meeting with Pres- exploded himself up behind the Afghanistan Times that six attack- ident Ghani the other day to dis- gate of the Parliament when Ma- ers who wanted to enter the Par- cuss parliamentary elections. soom Stanikzai, was going to be liament were immediately killed The two sides discussed dif- officially introduced to the law- by the security forces. The weap- ferent issues regarding the elec- makers for vote of confidence by ons depot was exploded in the tions including electoral reforms the Second Vice President Sarwar incidence said Karemi. He said one as well as people s trust over the Danish.
    [Show full text]
  • Biotope: Building an Iot Open Innovation Ecosystem for Smart Cities
    Received October 29, 2020, accepted November 21, 2020, date of publication November 30, 2020, date of current version December 29, 2020. Digital Object Identifier 10.1109/ACCESS.2020.3041326 bIoTope: Building an IoT Open Innovation Ecosystem for Smart Cities ASAD JAVED 1, (Member, IEEE), SYLVAIN KUBLER2, (Member, IEEE), AVLEEN MALHI 1, ANTTI NURMINEN1, JÉRÉMY ROBERT3, AND KARY FRÄMLING 1,4, (Member, IEEE) 1Department of Computer Science, Aalto University, 02150 Espoo, Finland 2CNRS, CRAN, Université de Lorraine, F-54000 Nancy, France 3Interdisciplinary Centre for Security, Reliability, and Trust, University of Luxembourg, L-2721 Luxembourg, Luxembourg 4Department of Computing Science, Umeå University, Mit-huset, 901 87 Umeå, Sweden Corresponding author: Asad Javed (asad.javed@aalto.fi) This work was supported in part by the European Union's Horizon 2020 Research and Innovation Programme under Grant 688203, in part by the Academy of Finland, Open Messaging Interface, under Grant 296096, and in part by the H2020 Project FINEST TWINS under Grant 856602. ABSTRACT The Internet of Things (IoT) has led towards a digital world in which everything becomes connected. Unfortunately, most of the currently marketed connected devices feed vertically-oriented closed systems (commonly referred to as vertical silos) which prevent the development of a unified global IoT. This issue is all the more valid in complex environments, such as smart cities, in which exceedingly large amounts of heterogeneous sensor data are collected, and in which platforms and stakeholders should also be able to interact and cooperate. Therefore, it is of utmost importance to move towards the creation of open IoT ecosystems to support efficient smart city service integration, discovery and composition.
    [Show full text]